OncoMatch/Clinical Trials/NCT02379377
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
Is NCT02379377 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Fluorine F 18 L-glutamate Derivative 18F-FSPG and Carbon C 11 Acetate for adult hepatocellular carcinoma.
Treatment: Fluorine F 18 L-glutamate Derivative 18F-FSPG · Carbon C 11 Acetate · Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose — This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out how far the disease has spread.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Cholangiocarcinoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify